Obesity medicine just got another serious data drop — and this one is a triple.
Retatrutide, from Eli Lilly, is a once-weekly shot designed to mimic three gut and metabolic hormones at once: GLP-1, GIP, and glucagon. On Sept. 29, 2026, Phase 3 TRIUMPH-1 results landed in the New England Journal of Medicine. The trial enrolled 2,339 adults with obesity without diabetes, randomized to retatrutide (4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.
At the highest dose, people lost about 25% of body weight on average, versus roughly 4% on placebo. In a planned extension out to 104 weeks, average loss at the top end reached about 30%. More than a third of participants on retatrutide lost 30% or more of their starting weight. Those are big numbers — and they are averages from a controlled trial, not a promise that every person will land in the same place.
The study also looked beyond the scale. In a knee-osteoarthritis subgroup, pain scores improved more on retatrutide than placebo. In an obstructive-sleep-apnea subgroup, hourly apnea events fell more on the drug. Cardiometabolic markers — blood pressure, triglycerides, LDL cholesterol — moved in healthier directions, and most participants who started with prediabetes no longer met that definition by the end, according to reporting on the trial.
Honesty check, because the desk owes you one: TRIUMPH-1 did not run head-to-head against dual agonists like tirzepatide. How retatrutide compares on weight loss and side benefits is still a pending question. Safety so far looks in the familiar GLP-1 family — mostly transient gastrointestinal symptoms — but rarer risks need longer, larger follow-up. This is powerful Phase 3 evidence for an investigational medicine. It is not a cure for obesity, and it is not approved therapy until regulators say so.
Why it matters
Millions of people live with obesity and the companions that travel with it — sore knees, interrupted sleep, blood pressure and cholesterol that will not behave. A medicine that moves weight and those day-to-day burdens is about how mornings feel, not only how a chart looks. Progress here is real; so is the work still left on comparison trials and long-term safety.
What’s next
Watch for head-to-head studies versus dual agonists, more safety follow-up, and the rest of Lilly’s TRIUMPH program as it matures toward regulatory review. For patients and clinicians, the useful stance is hopeful and grounded: strong Phase 3 signal, meaningful symptom relief in subgroups, and no skipping the fine print.
Sources: - Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (NEJM) - Most powerful obesity drug yet: people lost up to 25% of weight in trial (Ars Technica)